@alexionpharma.com
Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
Icon
PNG
About
Description
Alexion is a biopharmaceutical company headquartered in Boston, Massachusetts, United States. It was established in 1992 by Leonard Bell and Stephen Squinto with the goal of developing life-transforming therapies for patients with rare and severe diseases. The company's headquarters in Boston consists of its executive offices, research and development laboratories, as well as manufacturing facilities.
The location strategically places Alexion in proximity to leading academic and medical institutions, fostering collaboration and innovation. Alexion specializes in the development and commercialization of highly innovative therapies targeting rare diseases. Their flagship product is Soliris (eculizumab), the first and only therapeutic approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS).
Soliris is a monoclonal antibody that inhibits the complement system, a part of the immune system involved in these diseases. With a global presence, Alexion operates in over 50 countries worldwide. The company has several noteworthy subsidiaries, joint ventures, and partnerships.
One of their subsidiaries is Portola Pharmaceuticals, which specializes in developing novel therapeutics for the treatment of thrombosis and other hematologic conditions. Additionally, Alexion has partnered with numerous organizations and medical institutions to advance scientific research and expand its portfolio of rare disease treatments. In terms of market position, Alexion is considered a leader in the biopharmaceutical industry.
They have achieved significant success with Soliris, which generated billions of dollars in sales annually. The company's strong market presence can be attributed to their focus on rare diseases and their dedication to developing innovative therapies. Over the years, Alexion has experienced various major events and achievements.
In 2015, they acquired Synageva BioPharma for $8. 4 billion, expanding their rare disease portfolio. This acquisition added another blockbuster drug, Kanuma (sebelipase alfa), to their lineup.
Furthermore, in 2016, Alexion made a strategic move to relocate its headquarters from Connecticut to Boston, a decision that aimed to enhance their research and development capabilities. Currently, Alexion continues to advance its pipeline of therapies for rare diseases. They are committed to improving patients' lives through innovative treatments and expanding their global footprint.
As of the latest update, the company remains dedicated to addressing unmet medical needs and delivering transformative therapies to patients with rare diseases
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories